147 related articles for article (PubMed ID: 30707493)
1. Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors.
Deibler KK; Schiltz GE; Clutter MR; Mishra RK; Vagadia PP; O'Connor M; George MD; Gordon R; Fowler G; Bergan R; Scheidt KA
ChemMedChem; 2019 Mar; 14(6):615-620. PubMed ID: 30707493
[TBL] [Abstract][Full Text] [Related]
2. A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family.
Deibler KK; Mishra RK; Clutter MR; Antanasijevic A; Bergan R; Caffrey M; Scheidt KA
ACS Chem Biol; 2017 May; 12(5):1245-1256. PubMed ID: 28263556
[TBL] [Abstract][Full Text] [Related]
3. Modeling MEK4 Kinase Inhibitors through Perturbed Electrostatic Potential Charges.
Mishra RK; Deibler KK; Clutter MR; Vagadia PP; O'Connor M; Schiltz GE; Bergan R; Scheidt KA
J Chem Inf Model; 2019 Oct; 59(10):4460-4466. PubMed ID: 31566378
[TBL] [Abstract][Full Text] [Related]
4. MEK4 function, genistein treatment, and invasion of human prostate cancer cells.
Xu L; Ding Y; Catalona WJ; Yang XJ; Anderson WF; Jovanovic B; Wellman K; Killmer J; Huang X; Scheidt KA; Montgomery RB; Bergan RC
J Natl Cancer Inst; 2009 Aug; 101(16):1141-55. PubMed ID: 19638505
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
[TBL] [Abstract][Full Text] [Related]
7. Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors.
Chen T; Sorna V; Choi S; Call L; Bearss J; Carpenter K; Warner SL; Sharma S; Bearss DJ; Vankayalapati H
Bioorg Med Chem Lett; 2017 Dec; 27(24):5473-5480. PubMed ID: 29150397
[TBL] [Abstract][Full Text] [Related]
8. Scaffold oriented synthesis. Part 4: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions.
Akritopoulou-Zanze I; Wakefield BD; Gasiecki A; Kalvin D; Johnson EF; Kovar P; Djuric SW
Bioorg Med Chem Lett; 2011 Mar; 21(5):1480-3. PubMed ID: 21288717
[TBL] [Abstract][Full Text] [Related]
9. Scaffold oriented synthesis. Part 3: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing [2+3] cycloadditions.
Akritopoulou-Zanze I; Wakefield BD; Gasiecki A; Kalvin D; Johnson EF; Kovar P; Djuric SW
Bioorg Med Chem Lett; 2011 Mar; 21(5):1476-9. PubMed ID: 21282054
[TBL] [Abstract][Full Text] [Related]
10. Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma.
Kwong AJ; Pham TND; Oelschlager HE; Munshi HG; Scheidt KA
ACS Med Chem Lett; 2021 Oct; 12(10):1559-1567. PubMed ID: 34676038
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of indazole based analog sensitive Akt inhibitors.
Okuzumi T; Ducker GS; Zhang C; Aizenstein B; Hoffman R; Shokat KM
Mol Biosyst; 2010 Aug; 6(8):1389-402. PubMed ID: 20582381
[TBL] [Abstract][Full Text] [Related]
12. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
Laufer R; Ng G; Liu Y; Patel NK; Edwards LG; Lang Y; Li SW; Feher M; Awrey DE; Leung G; Beletskaya I; Plotnikova O; Mason JM; Hodgson R; Wei X; Mao G; Luo X; Huang P; Green E; Kiarash R; Lin DC; Harris-Brandts M; Ban F; Nadeem V; Mak TW; Pan GJ; Qiu W; Chirgadze NY; Pauls HW
Bioorg Med Chem; 2014 Sep; 22(17):4968-97. PubMed ID: 25043312
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis and Biological Evaluation of 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors.
Zhang Z; Zhao D; Dai Y; Cheng M; Geng M; Shen J; Ma Y; Ai J; Xiong B
Molecules; 2016 Oct; 21(10):. PubMed ID: 27782099
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold.
Liu J; Peng X; Dai Y; Zhang W; Ren S; Ai J; Geng M; Li Y
Org Biomol Chem; 2015 Jul; 13(28):7643-54. PubMed ID: 26080733
[TBL] [Abstract][Full Text] [Related]
15. Discovery of ( E)- N
Liu X; Wang B; Chen C; Qi Z; Zou F; Wang J; Hu C; Wang A; Ge J; Liu Q; Yu K; Hu Z; Jiang Z; Wang W; Wang L; Wang W; Ren T; Bai M; Liu Q; Liu J
J Med Chem; 2019 May; 62(10):5006-5024. PubMed ID: 31046271
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and structure-activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK).
Wang X; Xue G; Pan Z
Eur J Med Chem; 2020 Feb; 187():111918. PubMed ID: 31830635
[TBL] [Abstract][Full Text] [Related]
17. Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors.
Burch JD; Lau K; Barker JJ; Brookfield F; Chen Y; Chen Y; Eigenbrot C; Ellebrandt C; Ismaili MH; Johnson A; Kordt D; MacKinnon CH; McEwan PA; Ortwine DF; Stein DB; Wang X; Winkler D; Yuen PW; Zhang Y; Zarrin AA; Pei Z
J Med Chem; 2014 Jul; 57(13):5714-27. PubMed ID: 24918870
[TBL] [Abstract][Full Text] [Related]
18. The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors.
Wang HL; Cee VJ; Chavez F; Lanman BA; Reed AB; Wu B; Guerrero N; Lipford JR; Sastri C; Winston J; Andrews KL; Huang X; Lee MR; Mohr C; Xu Y; Zhou Y; Tasker AS
Bioorg Med Chem Lett; 2015 Feb; 25(4):834-40. PubMed ID: 25597005
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of N-cyclopropylbenzamide-benzophenone hybrids as novel and selective p38 mitogen activated protein kinase (MAPK) inhibitors.
Heo J; Shin H; Lee J; Kim T; Inn KS; Kim NJ
Bioorg Med Chem Lett; 2015 Sep; 25(17):3694-8. PubMed ID: 26115577
[TBL] [Abstract][Full Text] [Related]
20. The discovery of novel 3-aryl-indazole derivatives as peripherally restricted pan-Trk inhibitors for the treatment of pain.
Shirahashi H; Toriihara E; Suenaga Y; Yoshida H; Akaogi K; Endou Y; Wakabayashi M; Takashima M
Bioorg Med Chem Lett; 2019 Aug; 29(16):2320-2326. PubMed ID: 31235262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
